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Abstract It has been reported that interleukin-1beta (IL-1B)
genes play a crucial role in the genetic predisposition to
gastric cancer although there is no information about their role
in different subtypes of gastric cancer. We performed single
nucleotide polymorphism analysis of IL-1B in 241 gastric
cancers including early onset gastric cancers (EOGC), con-
ventional gastric cancers, and gastric stump cancers (GSCs) as
well as 100 control patients, using real-time polymerase chain
reaction and sequence analysis. The C allele was present in
60% of EOGCs, 59% of conventional gastric cancers, and
90% of GSCs, compared to 62% in the control group. Inter-
estingly, there was no difference between early onset and
conventional gastric cancer with respect to the IL-1B −31T>C
polymorphism distribution. A statistically significant differ-
ence in the presence of the C allele compared to the control
group was found in patients with gastric stump cancer ( p=
0.008) with the T allele conferring protection against gastric
stump cancer. In summary, we have shown that the IL-1B
−31C allele promoter polymorphism is significantly asso-
ciated with gastric stump cancer compared to the control
group. Although several molecular differences have been
identified between conventional gastric cancer and early
onset gastric cancer, the IL-1B −31 allele distribution is si-
milar between these two groups.
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Introduction
Although gastric cancer incidence decreases worldwide, it is
still the second most common cause of cancer-related death in
the world [35]. According to the Lauren classification [24],
gastric cancer is divided into two main histological types,
diffuse and intestinal. Gastric cancer results from a combi-
nation of environmental factors and accumulation of specific
genetic alterations. In conventional gastric cancer (presenting
>45 years old), environmental factors play a more important
role, compared to early onset gastric cancer (EOGC, present-
ing at ≤45 years old) where it is postulated that genetic
factors may be more important [20]. We have previously
shown that molecular differences exist between conventional
gastric cancer and EOGC [4–6, 29–32]. Apart from cases of
hereditary gastric cancer, it remains unclear what predisposes
the young patients to gastric cancer at such an early age.
Helicobacter pylori, is a class I carcinogen [16] and is
the main environmental factor causing gastric cancer [11,
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36]. H. pylori infection has been shown to range from
approximately 60% in the general population to approxi-
mately 84% in patients with gastric cancer [36]. Only a few
papers about H. pylori infection in gastric cancer patients
younger than 40 years have been published, all showing an
association between gastric cancer and H. pylori infection
[21, 28, 37]. H. pylori is involved in both intestinal and
diffuse types of gastric cancer, the latter type being more
common in EOGC [37].
Interleukin-1beta (IL-1B) is a key pro-inflammatory
cytokine, which regulates the expression of several genes
involved in inflammation. IL-1B is an endogenous inhibitor
of gastric acid secretion and is important in initiating and
enhancing the inflammatory response to H. pylori infection
[34, 43]. Although the production of IL-1B depends on
several factors, there is increasing evidence that the genetic
background plays a major role. Therefore, single nucleotide
polymorphisms (SNPs) in the IL-1B gene may be of im-
portance in gene transcriptional activity.
Several single nucleotide polymorphisms in IL-1B have
been studied, but many of these seem to be functionally in-
significant and not associated with predisposition to cancer
[7]. There are two biallelic polymorphisms at positions −31
and −511 in the promoter region of IL-1B, of which the
−31C allele and the −511T allele are in positive linkage dis-
equilibrium and associated with gastric cancer risk. It has
been reported that carriers of the IL-1B −31C allele, showed
higher plasmatic concentrations of IL-1B than subjects with
wild-type IL-1B genotype [14]. Upregulation of IL-1B is
involved in tumor-promoting effects such as invasiveness
[40], angiogenesis [38], and metastasis [45] and has been
recognized as negative prognostic factor, mainly in meta-
static cancer [27]. Conversely, an association between peptic
ulcer and the IL-1B −31T polymorphism has been described
[8, 9]. Bearing this information in mind, the IL-1B status of
patients with EOGC is of great interest. Whether these pa-
tients have a genetic predisposition for the carcinogenic
pathway in response to H. pylori infection has never been
investigated.
Several independent groups have found an association
between partial gastrectomy (mostly after gastroduodenal
ulcers) and increased risk for development of gastric cancer
[33, 39]. These so-called gastric stump cancers (GSCs) are
carcinomas occurring in the gastric remnant at least 5 years
after surgery for a benign disease [42]. This represents a
novel group in terms of IL-1B polymorphisms in that they
are patients who have a predisposition for gastroduodenal
ulcers yet have also developed gastric cancer. The IL-1B
status of gastric stump cancers has never been studied to
date.
In this study, we examined the distribution of the IL-1B
−31T>C polymorphism in 241 gastric cancers including
EOGC, conventional gastric cancer and GSC using real-time
polymerase chain reaction (PCR) and sequence analysis and
we investigated the relationship of IL-1B status with
histology and location of the tumor.
Materials and methods
Patients
We used 96 conventional gastric cancers (>45 years old)
obtained from the Academic Medical Centre, Amsterdam
diagnosed between 1993 and 2003. One hundred and fifteen
early onset gastric cancers (≤45 years old) diagnosed between
1980 and 2002, were obtained from 24 different institutions
throughout The Netherlands through the nationwide database
system and from the Department of Pathology at the Jorvi
Hospital (Espoo, Finland) and 30 gastric stump cancers from
the Amsterdam post-gastrectomy cohort [41]. The control
group consisted of 100 DNA samples from the Department
of Endocrinology at the Academic Medical Center, Amster-
dam as published previously [44]. The tumors were
classified by an experienced gastrointestinal pathologist
(GJAO) according to the Lauren classification, as can be
seen in Table 1. H. pylori vacA s region genotype and the
presence of the cagA gene were known for 29 of the EOGC
Table 1 Patients’ characteristics
No. of patients Age (range) Histology Location
Early onset gastric cancer (EOGC) 115 ≤45 (21–45 years) Intestinal—25 (22%) Cardia—9 (8%)
Diffuse—80 (70%) Non-cardia—66 (57%)
Mixed—10 (9%) Unknown—40 (35%)
Conventional gastric cancer 96 >45 (47–86 years) Intestinal—49 (51%) Cardia—49 (51%)
Diffuse—36 (38%) Non-cardia—41 (43%)
Mixed—11 (11%) Unknown—6 (6%)
Gastric stump cancer (GSC) 30 (54–85 years) Intestinal—26 (87%) Unknown
Diffuse—2 (7%)
Mixed—2 (7%)
Control group 100 (22–52 years) None None
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cases as detected by PCR followed by agarose gel
electrophoresis and as published previously [6]. H. pylori
infection was detected in 11 of 29 (37.9%) of these cases, a
percentage which is in accordance with published data
concerning The Netherlands population [25].
DNA isolation
DNA was isolated from formalin-fixed tissue using the
QIAamp DNA mini kit (Qiagen, Venlo, The Netherlands)
or the Puregene DNA isolation kit (Gentra, Minneapolis,
USA) according to the manufacturer’s instructions. Normal
tissue was obtained from a tumor-free lymph node, or
where necessary, from tissue with a small component of
neoplastic cells. DNA concentrations were measured using
the NanoDrop spectrophotometer (Isogen Life Science,
IJsselstein, The Netherlands).
Real-time PCR
The polymorphism −31T>C in the promoter region of IL-
1B was detected using the LightCycler 2.0 (Roche,
Mannheim, Germany) with 5′-cccctttcctttaacttgattgtgaaatc-
3′ and 5′-aggtttggtatctgccagtttctc-3′ (Applied Biosystems,
Foster City, USA) as primers and the fluorescent probes 6-
FAM-5′-CTGTTTTTATAGCTTTCA-3-MBG′, and VIC-5′-
CTGTTTTTATGGCTTTCA-3′-MGB (Applied Biosystems)
in a 20-μl reaction mixture containing 10 μl QuantiTect Probe
PCR Kit (Qiagen, Leusden, The Netherlands), 10 pmol
forward and reverse primer, 2 pmol of each probe, and 50
ng genomic DNA. PCR conditions were as follows: 94°C for
15min followed by 45 cycles of 94°C for 15 s and 60°C for 30
s. In each run, three positive control samples (TT, TC, and CC
allele) as confirmed twice on sequencing were used together
with water as a negative control.
Sequencing
To confirm the results from the real-time PCR, 10% of the
samples were sequenced. The promoter region was amplified
using the primers (forward) 5′-cccctttcctttaacttgattgtgaaatc-3′
and (reverse) 5′-aggtttggtatctgccagtttctc-3′ (Applied Biosys-
tems). PCR products were purified using the QIAquick PCR
purification kit (Qiagen), according to the manufacturer’s
instructions. The sequences were analyzed on an ABI 3100
automated sequencer (Applied Biosystems) using the ABI
Big Dye Terminator Cycle Sequence Kit (Applied Biosys-
tems) and the Genescan 2.1 software.
Statistics
The SPSS 14.0 software package was used for statistical
analysis. A chi-squared test was applied to determine whether
there was a statistical difference between the presence of the C
and T allele (p<0.05). The Hardy–Weinberg equilibrium was
assessed using the chi-squared test. A multinominal logistic
regression model was used to calculate the odds ratio for
developing gastric cancer depending on SNP status, and also
for adjusting for histological type and location (proximal
versus distal only for EOGC and conventional gastric cancer).
Results
The identification of a genetic risk profile for gastric cancer
could help the populations most at risk. Therefore, we eval-
uated the role of IL-1B −31T>C promoter polymorphism in
different subtypes of gastric cancer. The distribution of the
IL-1B −31T>C polymorphism was examined by real-time
PCR (see Fig. 1) in 241 cases of gastric cancer, including 96
conventional gastric cancers, 115 EOGCs, and 30 GSCs as
well as in 100 healthy control cases, and these results can be
seen in Table 2, where the number of each specific genotype
can be seen for each subtype of gastric cancer. In terms of
carriage of the C allele, this was found in 60% of EOGCs,
59% of conventional gastric cancer, 90% of GSCs, and 62%
of controls, as seen in the bottom row of Table 2. The IL-1B
polymorphism status was confirmed in 10% of our study
populations, using sequence analysis, an example of which
can be seen in Fig. 1. All genotypic distributions were in
Hardy–Weinberg equilibrium (p≥0.05).
A logistic regression model was used to determine the
statistical likelihood of developing different subtypes of
gastric cancer depending on the IL-1B SNP status. In this
regression model, carriage of the C allele was compared
between the different types of gastric cancer, with adjust-
ments made for both histology and location of the tumor (for
the categories of EOGC and conventional gastric cancer) and
corrected for histology only in the case of stump cancers. In
patients with GSC, carriage of the C allele conferred a sig-
nificant increased risk of the development of gastric cancer
with respect to the controls (p=0.008, OR=5.52, 95% con-
fidence interval 1.57–19.43). Carriage of the C allele (geno-
types CT and CC) in both EOGC and conventional gastric
cancer did not confer an increased risk of gastric cancer with
respect to the control group (p=0.76, OR 0.92, 95% con-
fidence interval 0.53–1.59 and p=0.71, OR 0.9, 95% con-
fidence interval 0.51–1.59, respectively).
Using a logistic regression model, the genotype distribu-
tion was also compared between EOGC, conventional gastric
cancer, GSC, and the control group. In the gastric stump
cancer group, the CC and CT genotypes predisposed to gastric
cancer with an OR of 5.33 (p=0.022, 95% confidence
interval 1.27–22.44) and 5.6 (p=0.009, 95% confidence
interval 1.54–20.40), respectively. No difference was found
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in genotype distribution between EOGCs and conventional
gastric cancers and the control group.
In addition, the IL-1B −31T>C genotype or carriage of the
C allele did not predispose to a specific location of gastric
cancer (cardia versus non-cardia, applicable to EOGC and
conventional gastric cancers only) or to a histological type.
Discussion
Inflammation is a central component of several chronic
diseases. IL-1B is an inducible gene that plays an important
role in both inflammation and carcinogenesis. The expres-
sion of IL-1B depends on varying individual susceptibility,
geographical location, and genetic factors. Genetic polymor-
phisms that alter the levels of IL-1B may have substantial
influence on cancer activity. In the present study, we focused
on the distribution of the −31T>C promoter polymorphism
of the human IL-1B gene in conventional gastric cancer,
EOGC, and GSC.
The IL-1B −31C allele is reported to be associated with
higher risk of gastric cancer [8, 9]. Interestingly, we did not
find an association between the pro-inflammatory genotype
of IL-1B −31 and predisposition to conventional or early
onset gastric cancer. The role of IL-1B −31T>C polymor-
phism in gastric cancer has been variable and the literature is
inconclusive. Positive associations between pro-inflammato-
ry genotypes of IL-1B −31 and higher risk of gastric cancer
have been previously reported in populations from Poland,
Scotland, and Mexico [8, 9, 12]. This is in contrast to studies
in Finland [18] and Brazil [13], and our current findings are
also in line with two published meta-analyses about the
association of IL-1B polymorphisms with gastric cancer in a
Caucasian population [3, 19]. It does appear that not all
Asian or white populations have demonstrated a predisposi-
tion for gastric cancer in association with pro-inflammatory
IL-1 polymorphisms and in some instances, studies found
that there was a positive association, but with novel markers
of the IL-1B gene [1]. So far, there is no clear explanation for
these conflicting results although the relatively small number
of gastric cancer cases (211) included in this particular study
may provide an explanation for the negative association
between the IL-1B marker and risk of GC. Zeng et al. [46]
reported that the IL-1B-genotype-dependent risk of gastric
cancer was limited to specific areas where the prevalence of
gastric cancer was low. This hypothesis, however, conflicts
with data showing an association between the IL-1B −31C
allele and gastric cancer in Poland and Portugal, two
countries both with high prevalence rates of gastric cancer
[8, 9, 35]. The effect of differing genetic and environmental
Table 2 Prevalence of IL-1B −31T>C genotype
Genotype of IL-1B −31T>C Early onset gastric cancer Conventional gastric cancer Gastric stump cancer Controls
CC 17/115 (15%) 21/96 (22%) 8/30 (27%) 19 (19%)
TC 52/115 (45%) 36/96 (37%) 19/30 (63%) 43 (43%)
TT 46/115 (40%) 39/96 (41%) 3/30 (10%) 38 (38%)
Carriage of the C allele 60% 59% 90% 62%
All percentages rounded to the nearest digit.
Fig. 1 Result of sequencing and LightCycler analysis. a An example
of the sequence analysis of the CC, CT, and TT IL-1B polymorphism.
b LightCycler analysis of CC, CT, and TT SNP genotypes at the −31
position of the promoter region of IL-1B using MGB probes. Upper
panel shows the FAM-labeled probe, visualized at 530 nm for
detection of the T allele; lower panel shows the VIC-labeled probe,
visualized at 560 nm for detection of the C allele
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factors on different populations may provide an explanation
for these conflicting reports. The importance of haplotype
context has been highlighted in recent literature where poly-
morphisms in metabolic genes and in CDH1 have been
shown to act in combination with smoking, alcohol con-
sumption, and H. pylori infection in the development of
gastric cancer [2, 17].
EOGC is a separate entity within gastric cancer and may
result from different genetic alterations that accumulate more
rapidly compared to conventional gastric cancer [6]. This is
the first study that investigates the pro-carcinogenic back-
ground of EOGC by evaluating the role of the IL-1B
−31T>C polymorphism in predisposition to EOGC. We
demonstrated that the distribution of the IL-1B −31T>C
polymorphism is not different between EOGC and the control
group and that there is no difference between conventional
gastric cancer and EOGC for the IL-1B −31 polymorphism.
Thus, once infected by H. pylori (which appears to occur at
the same rate as in conventional gastric cancers [6]), the IL-
1B status does not explain the increased risk of gastric
cancer in these young patients.
An intriguing subtype of gastric cancer is gastric stump
cancer, due to its gastroduodenal ulcer and partial gastrectomy
history and subsequent gastric cancer development. It is
described that gastric cancer and duodenal peptic ulcer disease
are inversely associated, have distinct gastric acid secretion
[10], and possess a distinct IL-1B −31T>C genotype distri-
bution. It is believed that subjects who develop duodenal
ulcers are actually protected from developing gastric cancer,
suggesting that the two outcomes are mutually exclusive [15].
In the GSC patients, who developed peptic ulcer and
gastric cancer, we found a statistically significant difference in
IL-1B −31T>C polymorphism compared to the control
group, with the C allele being associated with cancer. These
findings are surprising as although the patients in this unique
subgroup have a strong history of gastroduodenal ulcer, they
do not have the polymorphism reportedly associated with
ulcers but rather have a predilection for the C allele, which
may explain the increased cancer risk in these patients. Al-
though our gastric stump cancer group is small (30 patients),
it seems that the IL-1B −31T>C polymorphism influences
the prognosis of patients after partial gastrectomy. Although
individuals with duodenal ulcers generally do not have the C
polymorphism, the minority does appear to be at risk of
developing gastric stump cancer. Surgery removes the in-
flamed and H. pylori-ridden antrum and induces acid sup-
pression, thus converting these from an antrum-predominant
into a corpus-predominant phenotype (to some extent com-
parable to the pharmacological acid suppression group) [22,
23]. In addition, these patients with the C genotype are known
to have an associated high IL-1B output which further in-
creases the acid suppression thus increasing their risk of
subsequent development of gastric cancer.
Researchers have reported significant associations between
IL-1B promoter region polymorphisms and the anatomic site
of the tumor and histology. Machado et al. reported that the
IL-1B −511T (−31C) genotype is associated with an in-
testinal type of gastric cancer in a Portuguese population [26]
and Garza-Gonzalez et al. described the association between
the IL-1B −31C genotype and the risk of distal gastric cancer
in a Hispanic population [12]. We examined the associations
between IL-1B −31T>C polymorphisms and location of the
tumor or the histology and found no relation. This dis-
crepancy is most likely due to study size, as in our study,
where we have assessed a total of 241 gastric cancers, in
contrast to the 152 and 63 used by Machado et al. and
Garza-Gonzalez et al., respectively, and thus, it is likely that
there is no correlation between histology and IL-1B genotype.
On the other hand, the high rate of H. pylori infection in
countries such as Portugal may result in the IL-1B poly-
morphism playing a more important role in the development
of intestinal gastric cancer in this particular population.
In summary, this is the first study describing the role of the
IL-1B −31T>C polymorphism in EOGC and GSC. Although
EOGC appears to have a different genetic background com-
pared to conventional gastric cancer, we did not find any
differences in the IL-1B −31T>C polymorphism distribution.
Interestingly, our study has shown that the IL-1B −31C
genotype can contribute significantly to the development of
GSC.
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